Skip to content

Efficacy and safety analysis of hydromorphone combined with propofol intravenous anesthesia in elderly patients with PVP/PKP

Efficacy and safety analysis of hydromorphone combined with propofol intravenous anesthesia in elderly patients with PVP/PKP: a single-center clinical observational study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400094277
Enrollment
Unknown
Registered
2024-12-19
Start date
2025-01-01
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Local anesthesia group:15ml of 1% lidocaine +0.25% ropivacaine mixture (one vertebral body) was infiltrated layer by layer from skin to vertebral body
the sufentanil group:15ml of 1% lidocaine +0.25% ropivacaine mixture (one vertebral body) was infiltrated layer by layer from skin to vertebral body. Before peeling, sufentanil 0.1ug/kg+100ml0.9%NS wa
Hydromorphone group:15ml of 1% lidocaine +0.25% ropivacaine mixture (one vertebral body) was infiltrated layer by layer from skin to vertebral body. Before peeling, hydromorphone 0.01mg/kg+100ml0.9%NS

Sponsors

Jiangyin People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 65 years old; 2. Body mass index (BMI) 18.5-30kg/m^2; 3. ASA I-III level; 4. Patients undergoing percutaneous spondyloplasty or percutaneous balloon expansion kyphoplasty; 5. Voluntarily participated and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Chronic pain, chronic use of analgesics, psychotropic drugs (including opioids, NSAIDs, sedatives, antidepressants), alcohol abuse; 2. A history of opioid allergy; 3. Used sedatives, analgesics, anti-pruritus drugs 24 hours before surgery, and used monoamine oxidase inhibitors or antidepressants within 15 days before surgery; 4. Patients with abnormal increase of liver and renal function (ALT, AST, BUN, Cr) before operation and liver surgery; 5. History of recovery from abnormal surgical anesthesia; 6. Patients with previous sleep apnea, esophageal reflux disease history, COPD history; 7. Patients with difficult airway intubation are expected; 8. Participated in other drug trials within three months.

Design outcomes

Primary

MeasureTime frame
Number of intraoperative body movements;postoperative pain score(VAS);

Secondary

MeasureTime frame
time of operation;awakening time;Intraoperative respiratory depression;Postoperative nausea and vomiting;The first time to get out of bed after surgery;Preoperative cognitive function;postoperative cognitive function;

Countries

China

Contacts

Public ContactChen Jianqing

Jiangyin People's Hospital

cjqing8@sina.com+86 136 0616 6881

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026